Inhaltsbereich

Studien zum Verständnis der Kommunikationsmechanismen zwischen den Zellen

• Die Rolle der “Sprouty” Moleküle in der Zell-Zell-Komunikation

• Die Rolle der “Sprouty” Moleküle bei der Krebsentstehung

Studien zum Verständnis von Mechanismen, die Zellvermehrung direkt kontrollieren

• Die Rolle der “Aurora Kinasen“ im Zellzyklus von normalen und malignen Zellen

Eine vollständige Liste finden Sie in der PubMed Datenbank

Ausgewählte Publikationen

Jantscher, F., Pirker, C., Mayer, C.E., Berger, W., and Sutterluety, H. (2011) Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities. Molecular Cancer 10, 28.

Heinzle, C., Sutterluty, H., Grusch, M., Grasl-Kraupp, B., Berger, W., and Marian, B. (2011) Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opinion on therapeutic targets.

Pirker, C., Lotsch, D., Spiegl-Kreinecker, S., Jantscher, F., Sutterluty, H., Micksche, M., Grusch, M., and Berger, W. (2010) Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Experimental Dermatology 19, 1040-1047.

Haigl, B., Mayer, C.E., Siegwart, G., and Sutterluty, H. (2010) Sprouty4 levels are increased under hypoxic conditions by enhanced mRNA stability and transcription. Biological Chemistry 391, 813-821.

Mayer, C.E., Haigl, B., Jantscher, F., Siegwart, G., Grusch, M., Berger, W., and Sutterluty, H.  (2010) Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cell Mol Life Sci 67, 3299-3311.

Macheiner, D., Gauglhofer, C., Rodgarkia-Dara, C., Grusch, M., Brachner, A., Bichler, C., Kandioler, D., Sutterluty, H., Mikulits, W., Schulte-Hermann, R., et al. (2009). NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Research 69, 235-242.

Heffeter, P., Jakupec, M.A., Korner, W., Chiba, P., Pirker, C., Dornetshuber, R., Elbling, L., Sutterluty, H., Micksche, M., Keppler, B.K., et al. (2007). Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochemical Pharmacology 73, 1873-1886.

Sutterluty, H., Mayer, C.E., Setinek, U., Attems, J., Ovtcharov, S., Mikula, M., Mikulits, W., Micksche, M., and Berger, W. (2007). Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res 5, 509-520.

Steiner, E., Holzmann, K., Pirker, C., Elbling, L., Micksche, M., Sutterluty, H., and Berger, W. (2006). The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. Journal of Cell Science 119, 459-469.

Kubista, B., Trieb, K., Sevelda, F., Toma, C., Arrich, F., Heffeter, P., Elbling, L., Sutterluty, H., Scotlandi, K., Kotz, R., et al. (2006). Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24, 1145-1152.

Heffeter, P., Jakupec, M.A., Korner, W., Wild, S., von Keyserlingk, N.G., Elbling, L., Zorbas, H., Korynevska, A., Knasmuller, S., Sutterluty, H., et al. (2006). Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum (III)]trithiocyanate (KP772; FFC24). Biochemical Pharmacology 71, 426-440.

Penalva, L.O., Burdick, M.D., Lin, S.M., Sutterluety, H., and Keene, J.D. (2004). RNA-binding proteins to assess gene expression states of co-cultivated cells in response to tumor cells. Molecular Cancer 3, 24.

Wirbelauer, C., Sutterluty, H., Blondel, M., Gstaiger, M., Peter, M., Reymond, F., and Krek, W. (2000). The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. The EMBO journal 19, 5362-5375.
 
Neve, R.M., Sutterluty, H., Pullen, N., Lane, H.A., Daly, J.M., Krek, W., and Hynes, N.E. (2000). Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19, 1647-1656.

Sutterluty, H., Chatelain, E., Marti, A., Wirbelauer, C., Senften, M., Muller, U., and Krek, W. (1999). p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biology 1, 207-214.

Posch, M., Sutterluety, H., Skern, T., and Seiser, C. (1999). Characterization of the translation-dependent step during iron-regulated decay of transferrin receptor mRNA. The Journal of Biological Chemistry 274, 16611-16618.

Sutterluety, H., Bartl, S., Doetzlhofer, A., Khier, H., Wintersberger, E., and Seiser, C. (1998). Growth-regulated antisense transcription of the mouse thymidine kinase gene. Nucleic Acids Research 26, 4989-4995

Lisztwan, J., Marti, A., Sutterluty, H., Gstaiger, M., Wirbelauer, C., and Krek, W. (1998). Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. The EMBO journal 17, 368-383.

Sutterluety, H., and Seiser, C. (1997). Thymidine inhibits the growth-arrest-specific degradation of thymidine kinase protein in transfected L fibroblasts. Journal of Molecular Biology 265, 153-160.

Sutterluety, H., Bartl, S., Karlseder, J., Wintersberger, E., and Seiser, C. (1996). Carboxy-terminal residues of mouse thymidine kinase are essential for rapid degradation in quiescent cells. Journal of Molecular Biology 259, 383-392